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Abstract
Although depression with anxious distress appears to be a clinically relevant subtype of major depressive disorder
(MDD), whether it involves specific pathophysiology remains unclear. Inflammation has been implicated, but not
comprehensively studied. We examined within a large MDD sample whether anxious distress and related anxiety
features are associated with differential basal inflammation and innate cytokine production capacity. Data are from
1078 MDD patients from the Netherlands Study of Depression and Anxiety. In addition to the DSM-5 anxious distress
specifier, we studied various dimensional anxiety scales (e.g. Inventory of Depressive Symptomatology anxiety arousal
subscale [IDS-AA], Beck Anxiety Inventory [BAI], Mood and Anxiety Symptoms Questionnaire Anxious Arousal scale
[MASQ-AA]). The specifier was constructed using five self-report items from the IDS and BAI. Basal inflammatory
markers included C-reactive protein (CRP), interleukin (IL)-6 and tumor necrosis factor (TNF)-α. Innate production
capacity was assessed by 13 lipopolysaccharide (LPS)-stimulated inflammatory markers. Basal and LPS-stimulated
inflammation index scores were created. Basal inflammation was not associated with anxious distress (prevalence =
54.3%) in MDD patients, except for a modest positive association for BAI score. However, anxious distress was
associated with higher LPS-stimulated levels (interferon-γ, IL-6, monocyte chemotactic protein (MCP)-1, macrophage
inflammatory protein (MIP)-1α, matrix metalloproteinase (MMP)-2, TNF-α, LPS-stimulated index). Other anxiety
indicators (anxious distress specifier score, BAI, MASQ-AA) were also associated with increased innate production
capacity. Within a large MDD sample, the anxious distress specifier was associated with increased innate cytokine
production capacity but not with basal inflammation. Results from dimensional anxiety indicators largely confirm
these results. These findings provide new insight into the pathophysiology of anxious depression.
Introduction
Major depressive disorder (MDD) is often accompanied
by anxious features that can have a negative effect on the
outcome of depression1. Patients with MDD plus anxiety
symptoms were found to have poorer course trajectories1,2,
more suicidal ideation3–6 and worse treatment outcomes7–10
than patients with solely MDD. Therefore, it is relevant to
assess the pathophysiology of this anxious subtype
of MDD more closely. Studies have shown that anxious
depressed populations have distinct neurobiological corre-
lates when compared to non-anxious depressed popula-
tions11, for example stronger dysfunctions of the
hypothalamic–pituitary–adrenal axis12–14, increased neural
activation during functional magnetic resonance imaging
cognitive control tasks due to hypervigilance15 and deficits
in working memory activation16. Lately, inflammation has
gained interest as another important biological dysregula-
tion in depression.
Inflammation is one of the mechanisms implicated in
the pathophysiology of depression17–19, as it is found to be
more often present in depression than healthy controls in
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several meta-analyses20–22. Most studies have assessed
basal inflammation20–22. Innate cytokine production
capacity, i.e. responsivity of the immune system, has been
much less studied but associated with depression as
well23. Inflammation is also implicated in the pathophy-
siology of treatment-resistant depression19,24–26 and the
pathophysiology of anxiety disorders23,27–29. It has been
hypothesized that anxious depression could be seen as an
inflammatory phenotype since it shares common patho-
physiological pathways with inflammatory states30, but
the causality between depression and anxiety with
inflammation remains unclear. Miller and Raison17 sug-
gest in their review that the hypervigilance characteristic
of anxiety disorders might be part of the ‘pathogen host
defence’ hypothesis, where inflammatory systems are
activated in response to stressors leading to the develop-
ment of depression17. In addition, inflammasomes—pro-
tein complexes that recognize various stressors and
subsequently trigger activation of cytokines—may also
play an important role in the link between inflammation
and anxiety and depression17,31–33. Conversely, inflam-
matory processes in the brain may affect metabolic and
molecular pathways that influence neurotransmitter sys-
tems (e.g. monoamines and glutamate) which ultimately
affect neurocircuits that regulate behavior relevant for
anhedonia and anxiety17,34. To date, only two studies have
examined the link between inflammation and depression
with concurrent anxiety. One study showed higher
monocyte counts in patients with MDD and moderate-
severe to severe anxious distress than in those with mild
to moderate anxious distress35. The other study found
decreased venous blood basophil counts and increased
fragmented neutrophils in patients with MDD and high
levels of anxiety36. The findings of these studies reflect
alterations in white blood cell subset counts and indirectly
may point to alterations in the immune system, suggesting
the role of inflammation in the development of anxious
depression.
It is important to evaluate both basal inflammation as
well as innate production capacity, as these cover different
aspects of the immune system. Basal circulating inflam-
mation levels are usually low, have high within-person
variability23, and are highly influenced by lifestyle and
health factors20,23. Innate production capacity can be
evaluated by the expression of inflammatory markers in
response to ex vivo stimulation of blood by lipopoly-
saccharide (LPS)37. This production capacity may provide
more insight into the functioning of the immune system37
as it mimics the natural environment more closely38 and
is known to be under strong genetic control39. Our group
previously compared cytokine production capacity and
basal inflammation between persons with a current or
remitted depressive or anxiety disorders and healthy
controls23. Since anxious distress was not previously
examined but appears to be a clinically relevant subtype of
MDD, we now examined more specifically whether
anxious distress and related anxiety features are asso-
ciated with differential basal inflammation and innate
cytokine production capacity in a large MDD sample.
This study thus contributes to new insight into the
pathophysiology of anxious depression.
The investigation of differential inflammation in MDD
with concurrent anxiety features is complicated because
different diagnostic criteria have been used40. Levels of
concurrent anxiety in MDD are often determined by
established cut-off scores on different rating-scales40. This
leads to inconsistent evidence, but the new DSM-5
anxious distress specifier could establish more uni-
formity to studies on MDD with concurrent anxiety. Our
previous work has shown that the DSM-5 anxious distress
specifier is a clinically valid construct, and that it out-
performed the comorbidity indicator of DSM-IV-based
anxiety disorder diagnoses as a longitudinal predictor of
important clinical2 and treatment10 outcomes. We feel,
therefore, that it is important to examine whether the
anxious distress specifier is characterized by an underlying
biological profile, which could contribute to its prediction
of poor clinical and treatment outcomes.
The current study examines within a large cohort of
depressed patients whether anxious distress and related
anxiety features were associated with differential basal
inflammatory markers and innate cytokine production
capacity. The DSM-5 anxious distress specifier was con-
structed by items of standard self-report instruments that
approximated the DSM-5 criteria of the anxious distress
specifier. Besides the new DSM-5 anxious distress speci-
fier, we examined various dimensional anxiety indicators




Data were from the baseline assessment (September
2004 to February 2007) of The Netherlands Study of
Depression and Anxiety (NESDA), a longitudinal cohort
study examining the course and consequences of
depressive and anxiety disorders41. The sample consisted
of 2981 participants (18–65 years) with a current or prior
history of depressive and/or anxiety disorder and healthy
controls. To reflect different settings and stages of psy-
chopathology, participants were recruited from the com-
munity (19.0%), primary care (54.0%) and specialized
mental health-care settings (27.0%). Exclusion criteria
were insufficient command of the Dutch language or a
primary clinical diagnosis of other severe psychiatric
conditions. Data collection included an extensive inter-
view, blood collection, medical assessments and self-
reported questionnaires. The NESDA project was
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approved by the Ethical Committee of all participating
universities and all participants provided written informed
consent.
For the current study, we included 1115 patients with a
current (6-month recency) major depressive disorder
(MDD) diagnosis, assessed using the DSM-IV-based
Composite International Diagnostic Interview (CIDI,
version 2.1)42. Of these patients, 25 (2.2%) had incomplete
data on the DSM-5 anxious distress specifier, and 12
(1.1%) had no data available on both basal and innate
inflammatory markers, leaving 1078 MDD patients eligi-
ble for analysis. The primary focus of this study is the
anxious distress specifier. However, our previous work
showed that overlap between presence of the anxious
distress specifier and comorbid DSM-IV-based anxiety
disorder diagnoses is poor (Cohen kappa= 0.09)2,10,
indicating that these concepts are not directly compar-
able. To provide a comprehensive overview of anxiety
constructs in relationship to inflammation markers, we
also included other anxiety constructs in addition to
anxious distress. Patients with comorbid DSM-IV-based
anxiety disorder diagnoses were therefore not excluded
from the sample. The included MDD patients did not
differ from the remainder of the total NESDA sample in
terms of sex and physical activity, but were a little younger
(40.9± 12.0 vs. 42.4± 13.6 years, P= 0.003), had slightly
less educational years (11.7± 3.2 vs. 12.4± 3.3 years, P<
0.001), were more current smokers (n= 482, 44.7% vs. n
= 667, 35.0%, P< 0.001), had a higher alcohol intake
(>14/21 [female/male] drinks/week: n= 42, 3.9% vs. n=
71, 3.7%, P< 0.001) and had a somewhat higher BMI
(25.9± 5.4 vs. 25.4± 4.8 kg/m2, P= 0.011).
Anxious distress specifier
The anxious distress specifier was constructed by five
self-reported items from the Inventory of Depressive
Symptomatology (IDS)43 and the Beck Anxiety Inventory
(BAI)44 that matched directly with the five criteria for the
DSM-5 anxious distress specifier. Both questionnaires
assess symptoms in the past week on a 0–3 (not at all-
severe) scale. Symptoms were considered present when
scored ≥2 (i.e. moderate or severe). According to the
DSM-5 criterion, the anxious distress specifier was pre-
sent when a participant endorsed ≥2 of the following
symptoms: (1) feeling keyed up or tense (IDS item 7); (2)
feeling unusually restless (IDS item 24); (3) difficulty
concentrating because of worry (IDS item 15); (4) fear that
something awful might happen (BAI item 5); (5) feeling
that the individual might lose control of himself or herself
(BAI item 14). In addition to the presence of the specifier
(dichotomous indicator), the specifier score was also
determined (continuous indicator; range 0–15). Our pre-
vious work showed an adequate internal consistency
(Cronbach’s α= .71)2, and the specifier had predictive
validity for subsequent course and treatment response in
depressed patients2,10.
Other anxiety indicators
Current (6-month recency) anxiety disorder diagnoses
were assessed using the CIDI42 and included Social Pho-
bia, Panic disorder with or without Agoraphobia, Agor-
aphobia and Generalized Anxiety Disorder. A count of the
number of anxiety disorders was calculated (range 0–3).
Different anxiety (sub)scales were assessed: The Inven-
tory of Depressive Symptomatology anxiety arousal sub-
scale (IDS-AA)45, BAI44, Fear Questionnaire (FQ)46,
Mood and Anxiety Questionnaire Anxious Arousal sub-
scale (MASQ-AA)47, Anxiety Sensitivity Index (ASI)48
and the Penn State Worry Questionnaire anxiety subscale
(PSWQ)49. Some of these scales focus more on somatic
anxiety symptoms (i.e. IDS-AA, BAI and MASQ-AA),
others more on cognitive anxiety symptoms (i.e. anxious
distress specifier, FQ, ASI, PSWQ).
Basal and innate inflammatory markers
Basal inflammatory markers included C-reactive pro-
tein (CRP), interleukin (IL)-6 and tumor necrosis factor
(TNF)-α. Fasting blood samples were obtained by
laboratory staff (8–9 am) and kept frozen at −80°C. High-
sensitivity plasma CRP levels were measured in duplicate
by an in-house enzyme-linked immunosorbent assay
(ELISA) based on purified protein and polyclonal anti-
CRP antibodies (Dako, Glostrup, Denmark). Plasma IL-6
was measured in duplicate by a high-sensitivity ELISA
(PeliKine CompactTM ELISA; Sanquin, Amsterdam, The
Netherlands), and TNF-α was assayed in duplicate using a
high-sensitivity solid phase ELISA (Quantikine® HS
Human TNF-α Immunoassay; R&D systems Inc., Min-
neapolis, USA). Intra- and inter-assay coefficients of var-
iation were 5% and 10% for CRP, 8% and 12% for IL-6, and
10% and 15% for TNF-α. To obtain normal distributions,
the values of CRP, IL-6 and TNF-α were ln-transformed.
An overall measure of basal inflammation indicative of
more systemic inflammation was created by calculating a
basal inflammatory index as the standardized sum of all
three standardized ln-transformed basal markers.
Innate immune response of 17 cytokines was examined
at baseline by ex vivo LPS stimulation of blood. Data
collection for the LPS procedure was only conducted in
the last year of the baseline assessment and therefore LPS-
stimulated samples were only available in a (random)
subset of 1242 NESDA participants. Of the 1078 MDD
patients included in the current study, 454 patients had
available data on LPS-stimulated markers. Patients with
available data on these LPS-stimulated markers did not
differ from the remainder of the study sample in terms of
age, sex, education, depression severity and presence of
anxious distress. Serial venous whole blood samples were
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obtained in one 7-ml heparin-coated tube (Greiner Bio-
one, Monroe, North Carolina), of which 4.5 ml blood was
stimulated by addition of LPS (10 ng/ml blood; Escher-
ichia coli, Sigma, St. Louis, MO, USA) and these LPS-
stimulated samples were laid flat and incubated at a slow
rotation for 5–6 h at 37°C. Using a multi-analyte profile
(Human CytokineMAP A v 1.0; Myriad RBM, Austin,
USA), levels of granulocyte–macrophage colony-
stimulating factor (GM-CSF), interferon (IFN)-γ, IL-2,
IL-3, IL-4,IL-5, IL-6, IL-7, IL-8, IL-10, IL-18, monocyte
chemotactic protein-1 (MCP-1), macrophage inflamma-
tory protein (MIP)-1α, MIP-1β, matrix metalloproteinase-
2 (MMP-2), TNF-α and TNF-β were determined. Too few
values were obtained (valid n< 200) for several markers
(GM-CSF, IL-3, IL-5 and IL-7) and were therefore
excluded from analyses, leaving a total of 13 innate
inflammatory markers. All cytokines, except MMP-2 and
TNF-β, were ln-transformed to retrieve normal distribu-
tion patterns. To obtain a measure of overall innate
production capacity, an LPS-stimulated inflammation
index was calculated as the standardized sum of all 13
(normally distributed) standardized LPS-stimulated mar-
kers. Moderate to strong Pearson r correlations
(0.34–0.88) between individual LPS-stimulated markers
and LPS-stimulated index (Supplemental Table S5) sup-
ported the decision to combine all pro- and anti-
inflammatory LPS-stimulated markers, as was also done
in previous work23. In addition, the Pearson r correlation
between the basal index and LPS-stimulated index was
small (r= 0.16, P< 0.01; Table S5), supporting that these
cover different aspects of the immune system.
Covariates
Sociodemographic characteristics included age, sex and
lab/study site (Amsterdam, Leiden, Groningen, Heer-
enveen). Lifestyle and health covariates included smoking
status (never, former, current), alcohol intake (<1 drinks/
week; 1–14/1–21 [female/male] drinks/week; >14/21
[female/male] drinks/week), physical activity (Interna-
tional Physical Activity Questionnaire50, expressed in
1000 metabolic equivalent [MET]-minutes/week), num-
ber of self-reported chronic diseases under treatment
(heart disease, diabetes, stroke, lung disease, osteoar-
thritis, cancer, ulcer, intestinal problems, liver disease,
epilepsy, thyroid gland disease) and body mass index
(BMI; kg/m2). Depression severity was determined by the
Quick Inventory of Depressive Symptomatology (QIDS)51
with 16 items. To avoid overlap with the anxious distress
specifier, two overlapping IDS items (items 15 and 24)
were excluded resulting in a total score ranging from 0 to
24. Past-month medication use was based on drug con-
tainer inspection and classified according to the World
Health Organization (WHO) Anatomical Therapeutic
Chemical (ATC) classification system52. Antidepressant
medication use included use of selective serotonin reup-
take inhibitors (SSRI; ATC-code N06AB), tricyclic anti-
depressants (TCA; ATC-code N06AA) and other
antidepressants (Other AD; ATC-codes N06AF/N06AX).
Use of anti-inflammatory medication (M01A/M01B/
A07EB/A07EC) and statins (C10AA/C10B) was also
determined.
Statistical analyses
First, baseline characteristics and unadjusted levels of
basal and LPS-stimulated markers were described in the
whole MDD sample (N= 1078), and compared between
MDD patients with and without the specifier. Chi-square
tests were used for categorical variables, independent t-
tests for continuous variables, and Mann–Whitney U-
tests for non-normally distributed variables. Second,
adjusted associations between basal and LPS-stimulated
markers with presence of the anxious distress specifier
were analyzed using analyses of covariance. Associations
were adjusted for site, age, sex, and lifestyle and health
covariates. Cohen’s d53 was calculated to estimate effect
sizes. Finally, adjusted associations between the basal and
LPS-stimulated indices with various dimensional anxiety
indicators were analyzed using linear regression. We did
not correct for use of anti-inflammatory medication or
statins, as the prevalence of use was very low and non-
significantly different across groups. In all adjusted ana-
lyses, the specifier and other anxiety indicators were used
as independent variables, and inflammatory markers as
dependent variables.
Several other covariates (depression severity, SSRI use,
BMI) were not adjusted for in the primary analysis, but
adjustment for these are reported in the Supplement (see
Supplemental Tables S2 and S3). Correction for these
factors may be considered an overcorrection given that
patients with MDD meeting criteria for the anxious dis-
tress specifier already have a higher depression severity by
definition (i.e. more symptoms are required). It has also
been suggested that anxiety may be an epiphenomenon of
the more severe forms of MDD, rather than a distinct
phenomenon9. Antidepressant use is also likely to reflect
depression severity, and prior analyses have shown only
some restricted associations with LPS-stimulated inflam-
matory indicators23. It has been shown that BMI affects
basal inflammation more strongly than innate produc-
tion23. Adipose tissue produces cytokines and may lie on
the same pathway as inflammation, which can have a
mediating effect20. Therefore, correction for BMI may be
considered an overcorrection. Statistical analysis was
conducted with SPSS, version 22 (IBM Corp.: Armonk,
New York), and all statistical tests were two-sided. Since
we analyzed correlated measures that reflect one central
concept, we corrected for multiple testing using the
Benjamini–Yekutieli method54,55 that takes dependency of
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test statistics into account. We calculated an adjusted P-
value of 0.012 correcting for the number of tests per-
formed (N= 34). Results with P-values smaller than the
adjusted threshold of 0.012 were considered significant.
Results
The MDD sample (N= 1078) had a mean age of 40.9
(SD= 12.05) years, 67.3% were female, had a mean QIDS
score of 10.8 (SD= 4.4) and 65.5% had a concurrent
anxiety disorder. The anxious distress specifier was pre-
sent in over half of the MDD patients (n= 585; 54.3%)
(Table 1). In addition, presence of the anxious distress
specifier poorly overlapped with presence of any comor-
bid DSM-IV-based anxiety disorder diagnosis (Cohen
kappa= 0.09). Quite a few MDD persons with comorbid
anxiety disorders (n= 253, 23.5%) do not fulfill the
anxious distress specifier, and vice versa, quite some
MDD persons with anxious distress (n= 132, 12.2%) do
not fulfill criteria for a comorbid DSM-IV-based anxiety
disorder, indicating that concepts are not directly
comparable.
Sociodemographics were comparable between MDD
patients with and without the anxious distress specifier,
with the exception of one year less education in patients
meeting criteria for the specifier (P< 0.001). In addition,
patients with the specifier, compared to those without,
had a higher depression severity (P< 0.001) and were
more likely to use SSRIs (P= 0.016). Patients with the
specifier reported more alcohol intake (P= 0.002), had a
higher BMI (P= 0.028), and reported more chronic dis-
eases (P= 0.012). As expected, all anxiety indicators were
significantly higher in the MDD patients with the specifier
(P< 0.001) (Table 1).
Unadjusted levels of all basal inflammatory markers did
not significantly differ between MDD patients with and
without the specifier (Table 2). In contrast, several
unadjusted LPS-stimulated inflammation levels (MMP-2
and LPS-stimulated index) were significantly higher in
patients with than without the specifier (Table 2).
Adjusted analyses were adjusted for sociodemographics
(i.e. site, age, sex) and lifestyle and health covariates (i.e.
smoking status, alcohol intake, physical activity, number
of self-reported chronic diseases under treatment). We
determined the specific effects of all selected covariates on
the basal and LPS-stimulated inflammation index in one
multiple linear regression model for each index. The basal
inflammation index was associated with smoking status
(β= 0.09, P= 0.001), QIDS severity (β= 0.13, P< 0.001)
and BMI (β= 0.36, P< 0.001), whereas the LPS-
stimulated inflammation index was associated with sex
(β=−0.16, P< 0.001), site (β=−0.23, P< 0.001) and
smoking status (β= 0.14, P= 0.003). The adjusted dif-
ference in levels of basal markers remained non-
significant between MDD patients with and without
anxious distress (Fig. 1; Table S1). Interestingly, for the
innate production capacity, effects of anxious distress
appeared stronger after adjustment for socio-
demographics and important lifestyle and health covari-
ates with small to medium effect sizes. A higher number
of adjusted (6 out of 13) than unadjusted (1 out of 13)
levels of the LPS-stimulated markers (i.e. IFN-γ, IL-6,
MCP-1, MIP-1α, MMP-2, TNF-α) as well as the LPS-
stimulated inflammation index were significantly higher
in MDD patients with anxious distress (Fig. 1; Table S1).
Adjusted levels of three out of these six markers remained
significantly higher in patients with anxious distress after
adjustment for depression severity (QIDS score)
(Table S2). After adjustment for SSRI use and BMI, all six
LPS-stimulated markers and the LPS-stimulated index
remained significantly higher (all P-values <0.012) and
effect sizes were comparable after additional adjustment
(Table S2). We specifically aimed to examine within a
large sample of MDD whether anxious distress was
associated with differential inflammation. No healthy
control group is required to answer this particular
research question. Nevertheless, we ran additional ana-
lyses with the inclusion of healthy controls to place the
main findings of MDD with anxious distress in a broader,
conceptual framework and to determine whether
increased innate cytokine production capacity, as com-
pared to healthy controls, was indeed the most dysregu-
lated in MDD with anxious distress and that MDD
without anxious distress differed less in this respect.
Therefore, we not only examined whether innate cytokine
production capacity was increased in MDD with anxious
distress when compared to MDD without anxious dis-
tress, but also examined whether innate cytokine pro-
duction capacity was increased in MDD with anxious
distress when compared to healthy controls. Adjusted
analyses were repeated for the significant associations
with the 6 out of 13 LPS-stimulated markers and LPS-
stimulated index with the addition of a healthy control
group. NESDA participants without a lifetime depressive
and anxiety disorder and who had available data on LPS-
stimulated markers were included in the control group (N
= 297). All LPS-stimulated levels and index remained
significant between MDD patients with anxious distress
and controls, with the exception of IFN-ɣ (P= 0.144)
(Figure S1A). In contrast, all LPS-stimulated levels and
index were non-significant between MDD patients with-
out anxious distress and controls (Figure S1B).
When examining associations between the inflamma-
tion indices with various anxiety indicators within the
MDD sample, a positive association was found between
the basal inflammation index and BAI score (P= 0.011) of
modest strength after adjustment for sociodemographics
and lifestyle and health factors (Table 3). For the seven
other anxiety indicators, no associations with the basal
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Table 1 Baseline characteristics in patients with current (past 6 months) MDD, and with and without the DSM-5 anxious
distress specifier





N = 1078 N = 585 N = 493
Sociodemographic characteristics
Age, years, mean ± SD 40.9 ± 12.05 41.3 ± 12.0 40.5 ± 12.1 0.288 1078
Sex, female, n (%) 725 (67.3) 390 (66.7) 335 (68.0) 0.654 1078
Education, years, mean ± SD 11.7 ± 3.2 11.2 ± 3.3 12.1 ± 3.1 <0.001 1078
Laboratory site, n (%)
Amsterdam 391 (36.3) 214 (36.6) 177 (35.9) 0.163 1078
Leiden 394 (36.5) 223 (38.1) 171 (34.7)
Groningen 205 (19.0) 99 (16.9) 106 (21.5)
Emmen 64 (5.9) 39 (6.7) 25 (5.1)
Heerenveen 24 (2.2) 10 (1.7) 14 (2.8)
Clinical characteristics
Depression severity, QIDS score, mean ± SD 10.8 ± 4.4 12.9 ± 3.8 8.3 ± 3.8 <0.001 1078
Antidepressant medication use, n (%)
Tricyclic antidepressant 44 (4.1) 23 (3.9) 21 (4.3) 0.786 1078
Selective serotonin reuptake inhibitor 316 (29.3) 188 (32.1) 128 (26.0) 0.027 1078
Other antidepressant 120 (11.1) 70 (12.0) 50 (10.1) 0.343 1078
Lifestyle and health factors
Smoking status, current smoker, n (%) 482 (44.7) 268 (45.8) 214 (43.4) 0.731 1078
Alcohol intake, n (%)
<1 drink a week 438 (40.6) 261 (44.6) 177 (35.9) 0.003 1078
1–14/1–21 (women/men) drinks a week 598 (55.5) 297 (50.8) 301 (61.1)
>14/>21 (women/men) drinks a week 42 (3.9) 27 (4.6) 15 (3.0)
Physical activity (1000 MET-min), mean ± SD 3.5 ± 3.1 3.5 ± 3.1 3.6 ± 3.2 0.318 1078
Body mass index (kg/m2), mean ± SD 25.9 ± 5.4 26.2 ± 5.5 25.5 ± 5.3 0.028 1078
Number of chronic diseases, n (%)
0 579 (53.7) 294 (50.3) 285 (57.8) 0.010 1078
1 328 (30.4) 182 (31.1) 146 (29.6)
≥2 171 (15.9) 109 (18.6) 62 (12.6)
Systemic anti-inflammatory medication, n (%) 52 (4.8) 29 (5.0) 23 (4.7) 0.824 1078
Statin use, n (%) 76 (7.1) 41 (7.0) 35 (7.1) 0.954 1078
Anxiety constructs
Any current anxiety disorder, n (%) 706 (65.5) 453 (77.4) 253 (51.3) <0.001 1078
Number of anxiety disorders, median (IQR) 1.0 (0.0–2.0) 1.0 (1.0–2.0) 1.0 (0.0–1.0) <0.001 1078
IDS anxiety arousal subscale, mean ± SD 16.4 ± 4.2 18.7 ± 3.5 13.7 ± 3.1 <0.001 1077
Beck Anxiety Inventory, mean ± SD 18.1 ± 11.2 24.5 ± 10.4 10.5 ± 6.6 <0.001 1078
Fear Questionnaire, mean ± SD 33.7 ± 21.6 41.2 ± 22.0 24.8 ± 17.4 <0.001 1078
MASQ anxious arousal subscale, mean ± SD 18.9 ± 6.9 21.9 ± 7.1 15.5 ± 4.7 <0.001 894
Anxiety Sensitivity Index, mean ± SD 17.3 ± 10.3 20.8 ± 10.8 13.4 ± 8.0 <0.001 910
Penn State Worry Questionnaire, mean ± SD 38.2 ± 9.9 41.7 ± 8.8 34.3 ± 9.6 <0.001 906
IDS Inventory of Depressive Symptomatology, MASQMood and Anxiety Symptoms Questionnaire, MDD major depressive disorder, MET metabolic equivalent, QIDS,
Quick Inventory of Depressive Symptomatology. aFor P-value: t-tests were used for continuous variables; Chi-square analyses were used for dichotomous variables;
Mann–Whitney U-tests were used for non-normal distributed variables
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index were found. In contrast, a higher number of positive
associations were found between the LPS-stimulated
inflammation index and various indicators of high anxi-
ety: the anxious distress specifier score (P= 0.001), the
BAI (P< 0.001) and the MASQ-AA (P= 0.007) (Table 3).
Effects for some anxiety indicators became non-
significant after adjustment for QIDS score and only
MASQ-AA became marginally significant (P= 0.017)
after adjustment for SSRI use, but all indicators remained
significant when adjusting for BMI (all P-values <0.012)
(Table S3).
In a post-hoc analysis we evaluated the correlation
between the anxiety measures to see whether the
dimensional anxiety scales with more somatic items were
strongly correlated (Table S4). Correlations between the
somatic-oriented IDS-AA, BAI and MASQ-AA were
strong (0.63–0.74), whereas these were moderate
(0.35–0.55) between the cognitive-oriented anxiety indi-
cators (FQ, ASI, PSWQ) (Table S4).
Discussion
This study is the first to examine whether anxious dis-
tress and related anxiety features are associated with
dysregulated basal inflammatory markers and innate
cytokine production capacity within a large MDD sample.
Our most important finding is that higher innate pro-
duction capacity, rather than higher basal inflammation,
was associated with anxious distress in a large MDD
sample. Anxious distress in MDD patients (present in
54.3%) was not associated with higher basal inflammation,
but a modest positive association was found for BAI score.
However, anxious distress was associated with higher
LPS-stimulated inflammation levels (i.e. IFN-γ, IL-6,
MCP-1, MIP-1α, MMP-2, TNF-α and LPS-stimulated
Table 2 Unadjusted levels of basal and LPS-stimulated inflammatory markers in patients with current (past 6 months)
MDD, and with and without the anxious distress specifier





N = 1078 N = 585 N = 493
Basal inflammatory markers
CRP (mg/l), med (IQR) 1.18 (0.54–2.93) 1.16 (0.53–2.81) 1.23 (0.56–3.01) 0.844 1011
IL-6 (pg/ml), med (IQR) 0.81 (0.51–1.33) 0.81 (0.52–1.29) 0.77 (0.50–1.35) 0.436 1076
TNF-α (pg/ml), med (IQR) 0.80 (0.60–1.10) 0.80 (0.60–1.10) 0.80 (0.60–1.15) 0.886 1069
Basal inflammation index, mean ± SD 0.06 ± 1.0 0.02 ± 0.98 −0.02 ± 1.02 0.572 1003
LPS-stimulated inflammatory markers
IFN-γ (pg/ml), med (IQR) 10.20 (7.31–14.00) 10.50 (8.00–14.03) 9.82 (6.22–14.00) 0.065 454
IL-2 (pg/ml), med (IQR) 9.24 (6.39–13.70) 9.51 (6.79–13.88) 8.59 (5.78–12.60) 0.037 454
IL-4 (pg/ml), med (IQR) 9.03 (4.23–15.23) 9.03 (4.23–15.00) 9.14 (4.23–15.90) 0.958 454
IL-6 (ng/ml), med (IQR) 26.70 (18.05–34.80) 27.60 (19.90–37.20) 25.05 (16.38–33.55) 0.015 453
IL-8 (ng/ml), med (IQR) 11.20 (7.90–16.70) 11.40 (8.16–17.40) 10.60 (7.47–15.98) 0.170 453
IL-10 (pg/ml), med (IQR) 203.50 (114.75–380.50) 205.50 (121.25–409.25) 200.00 (108.75–339.25) 0.131 454
IL-18 (pg/ml), med (IQR) 254.00 (209.00–314.25) 260.00 (214.75–316.50) 249.50 (202.00–313.75) 0.234 454
MCP-1 (ng/ml), med (IQR) 1.60 (1.05–2.33) 1.70 (1.17–2.46) 1.57 (0.91–2.22) 0.020 454
MIP-1α (ng/ml), med (IQR) 18.80 (12.70–25.75) 20.00 (13.60–26.65) 17.05 (11.70–23.83) 0.014 453
MIP-1β (ng/ml), med (IQR) 240.00 (169.00–316.00) 244.00 (170.50–316.00) 228.50 (166.50–316.00) 0.143 453
MMP-2 (ng/ml), mean ± SD 74.12 ± 18.75 76.74 ± 17.73 70.67 ± 19.54 0.001* 454
TNF-α (ng/ml), med (IQR) 2.77 (1.87–4.01) 2.90 (1.96–4.27) 2.67 (1.69–3.77) 0.022 453
TNF-β (pg/ml), mean ± SD 328.03 ± 135.38 339.74 ± 124.26 312.62 ± 147.68 0.039 454
LPS inflammation index, mean ± SD 0.12 ± 0.85 0.23 ± 0.70 −0.03 ± 1.00 0.002* 453
CRPC-reactive protein; IFNinterferon; ILinterleukin; LPS lipopolysaccharide; MCP monocyte chemotactic protein, MDD major depressive disorder; med median; MIP
macrophage inflammatory protein; MMP matrix metalloproteinase; TNFtumor necrosis factor. aFor P-value: t-tests were used for continuous variables; Mann–Whitney
U-tests were used for non-normal distributed variables. *Results survive the Benjamini–Yekutieli correction for multiple comparisons threshold of <0.012
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inflammation index). Other indicators of high anxiety (i.e.
anxious distress specifier score, BAI and MASQ-AA
scores) confirmed an increased innate cytokine produc-
tion capacity in MDD patients scoring high on the anxiety
dimension.
The results support the hypothesis that patients with
the anxious distress specifier may have different under-
lying biological profiles than patients without this speci-
fier, which could contribute to earlier findings showing
that the anxious distress specifier predicts poorer course
and treatment outcomes2,10. Our study supports the
recent suggestion of the specific involvement of inflam-
mation in the development of anxious depression36.
Anxious depression has distinct neurobiological corre-
lates that separates it from MDD alone11–16, and our
results further support and extend this in light of
inflammation.
Anxious distress within MDD patients was not asso-
ciated with higher basal inflammation. Possibly, this may
be due to the fact that basal inflammation levels are
usually low and have high within-person variability,
making it harder to detect immune dysregulations23. Also,
basal inflammation levels are known to be rather strongly
influenced by lifestyle and (somatic) disease factors20,23.
However, even the unadjusted levels of basal inflamma-
tion did not differ between MDD patients with and
without anxious distress. In contrast to our findings, one
study showed that MDD patients with moderate-severe to
severe anxious distress tended to have higher CRP levels
than those with mild to moderate anxious distress35.
However, the difference in CRP levels was non-significant
after adjustment and no other basal inflammation mar-
kers were assessed in that study. Serum concentration of
CRP is a complicated diagnostic biomarker of depression.
While synthesis of the acute-phase protein CRP in the
liver is mainly induced by IL-6 and IL-1, a range of other
factors might induce its synthesis as well56. Although
previous studies have indicated elevated CRP in depressed
patients compared with healthy controls20,57, interest-
ingly, it has been shown that the rs1205(G/A) genetic
Fig. 1 Adjusted difference in basal and innate inflammatory markers between MDD patients with versus without (ref) the DSM-5 anxious distress
specifier. *Results survive the Benjamini–Yekutieli correction for multiple comparisons threshold of <0.012, adjusted regression coefficients and error
bars (95% CI) of ln-transformed inflammatory markers (MMP-2 and TNF-β were also ln-transformed for easy comparison). CRP C-reactive protein, IFN
interferon, IL interleukin, LPS lipopolysaccharide, MCP, monocyte chemotactic protein, MDD major depressive disorder, MIP, macrophage
inflammatory protein, MMP matrix metalloproteinase, TNF tumor necrosis factor. Based on analyses of covariance. Adjusted for site, age, sex, smoking
status, alcohol intake, physical activity and number of chronic diseases under treatment
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polymorphism of the CRP gene is associated with both
lower CRP levels and greater risk of depression58,59. Some
of this complexity likely arises from the biological het-
erogeneity in depression risk and resilience factors within
the MDD population. Cytokines on the other hand are
more specific cell-based measures of inflammation rather
than the non-specific inflammation marker CRP, and it
has been shown that relevant genetic variants of specific
cytokines were associated with increased risks of depres-
sion development59. This could explain why we find
increased levels of several cytokines in persons with MDD
and anxiety but not of CRP. A modest positive association
was found for higher basal inflammation and BAI score,
possibly because this anxiety indicator has a greater focus
on somatic, rather than cognitive, anxiety symptoms.
Interestingly, for innate production capacity, associa-
tions with the anxious distress specifier became stronger
after adjustment for several important lifestyle and health
factors. Also, all findings remained significant after addi-
tional adjustment for BMI and SSRI use, supporting the
suggestion that innate production capacity is not highly
influenced by lifestyle and health status, in line with
previous findings23. After additional adjustment for
depression severity, some of the positive associations
between presence of the specifier and higher levels of
LPS-stimulated inflammatory markers and index in MDD
patients diminished to non-significance. In addition,
although the value of adjusting for SSRI use, BMI and
overall depression severity is unclear and can be con-
sidered as overcorrection, we nevertheless corrected for
these factors in additional analyses, showing that main
findings were not different after adjustment for these
extra factors. Moreover, these findings were extra con-
firmed when analyses were repeated with the addition of a
healthy control group. Thus, it seems that the link
between innate production capacity and anxious distress
in MDD is not mainly driven by depression severity but
likely relies on anxiety aspects.
Higher innate production was positively associated with
anxiety indicators (i.e. BAI and MASQ-AA scores) with a
greater focus on somatic anxiety symptoms, and these
indicators were strongly correlated. This may imply that
the association between anxious distress in MDD and
higher innate production is mainly driven by somatic
anxiety symptoms. This is in line with earlier research
where somatic, but not cognitive, symptoms of anxiety
and depression were associated with basal inflamma-
tion60. Moreover, somatic anxiety symptoms may reflect
the hypervigilance characteristic of anxiety disorders—
which was suggested to be part of the ‘pathogen host
defence’ hypothesis17, thereby the results support this
hypothesis. It is also possible that somatic anxiety symp-
toms are associated with increased sympathetic and
decreased parasympathetic autonomic activity61, since the
autonomic nervous system is associated with higher
inflammation levels18,62,63. Another possibility for the
anxiety-inflammation link is that inflammatory markers in
the brain affect metabolic and molecular pathways that
influence neurotransmitter systems (e.g. monoamines and
glutamate) which ultimately affect neurocircuits regulat-
ing anxiety17,34. It is also possible that anxiety, reflected as
psychological stress, may induce inflammasome pathways
leading to inflammation and ultimately to depression17,32.
The innate inflammatory response is under strong genetic
control39 with heritability estimates ranging from 53 to
86% in non-diseased populations39,64. It may be possible
that the anxious subtype of MDD has shared genetics with
the innate production capacity. Future research should
further examine this genetic link. Another possible
explanation for the found associations between higher
LPS-stimulated levels and anxious distress in MDD
patients may be that the inflammatory signals become
amplified after ex vivo LPS stimulation making it easier to
find associations, rather than that basal inflammation and
innate production capacity are truly different immune
concepts.
With regard to different subtypes of MDD and inflam-
matory dysregulations, it has been shown in some studies,
but not all, that elevated basal inflammation levels were
more common in atypical than in melancholic depression
Table 3 Adjusted associations between basal
inflammation index and LPS-stimulated inflammation
index with various dimensional anxiety constructs in






β Pa R2 β Pa R2
Anxious distress specifier
score
0.04 0.194 0.055 0.15 0.001* 0.135
Number of anxiety disorders 0.03 0.363 0.055 0.11 0.021 0.123
IDS anxiety arousal subscale 0.07 0.021 0.059 0.10 0.026 0.122
Beck Anxiety Inventory 0.08 0.011* 0.060 0.19 <0.001* 0.146
Fear Questionnaire 0.06 0.051 0.058 0.09 0.063 0.119
MASQ anxious arousal scale 0.04 0.256 0.055 0.14 0.007* 0.156
Anxiety Sensitivity Index 0.01 0.867 0.054 0.09 0.061 0.148
Penn State Worry
Questionnaire
0.01 0.873 0.054 0.09 0.070 0.146
IDS Inventory of Depressive Symptomatology, LPS lipopolysaccharide, MASQ
Mood and Anxiety Symptoms Questionnaire; MDDmajor depressive disorder.
aBased on linear regression analyses. Adjusted for site, age, sex, smoking status,
alcohol intake, physical activity and number of chronic diseases under
treatment. *Results survive the Benjamini–Yekutieli correction for multiple
comparisons threshold of <0.012
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and healthy controls65. Our group previously found that
an atypical and melancholic symptoms subscale were to
the same extent associated with increased innate pro-
duction capacity, but these associations were no longer
significant after health adjustment23. However, our find-
ings show that after lifestyle and health adjustment,
anxious distress in MDD patients is associated with
increased innate production capacity, but not with basal
inflammation. Post-hoc analyses showed that when
repeating the analyses while adjusting for both the aty-
pical66 and melancholic67 symptom subscale together in
one model, the significant associations between 6 out of
13 LPS-stimulated markers and LPS-stimulated index
with the anxious distress specifier remained significant.
This clearly indicates that these are unrelated findings.
The anxious distress specifier appears to identify a
clinically relevant group of patients who may have a poor
course and poor treatment response2,10, and which seems
to involve a stronger innate cytokine production capacity
that separates it from MDD alone. It has been shown in
patients with high baseline inflammatory biomarkers that
anti-inflammatory treatment with TNF-α antagonists may
improve depressive symptoms68. A meta-analysis by
Kohler and colleagues (2014)69 suggested the positive
antidepressant effects of anti-inflammatory treatment
such as nonsteroidal anti-inflammatory drugs and
cyclooxygenase-2 inhibitors in depression but this finding
was uncertain because of high heterogeneity. This
underscores the need to identify depressive subgroups
with high inflammation that may benefit from anti-
inflammatory treatments. Our study contributes to the
reduction in MDD heterogeneity, and supports the idea
that the anxious MDD subgroup may specifically benefit
from anti-inflammatory agents or new antidepressants
with a target on inflammation.
Several limitations should be noted. The specifier used
for this study was constructed by self-reported proxy
items instead of clinician-based assessments2. However,
results from our previous study demonstrated that our
specifier reflected a valid conceptual assessment for
anxious depression with significant discriminant perfor-
mance and convergent and predictive validity2. We
selected patients who had an MDD diagnosis with a 6-
month recency in order to obtain a large enough sample,
which has also been utilized in our previous work
examining the longitudinal course and treatment impact
of the anxious distress specifier2,10. Of our MDD sample,
almost all (95%) had truly evidence of recent symptoms as
indicated by either the presence of MDD with a 1-month
recency or an IDS score ≥14, indicating clinically relevant
depression severity symptoms. Similar results were
obtained when removing the 5% not meeting this cur-
rency criteria, showing that inclusion of these patients did
not impact our results. While we adjusted for number of
chronic somatic diseases under treatment in our primary
analyses as a measure of overall burden of somatic disease,
we did not adjust for a specific type of somatic disease.
However, we determined the independent effects of the
various somatic diseases, and found that only chronic
non-specific lung diseases (i.e. asthma, chronic bronchitis
and pulmonary emphysema) had a significant effect on
the LPS-stimulated inflammatory index (P= 0.047).
When adjusting for all specific types of somatic diseases,
this did not change our conclusions which further sup-
ports the decision to adjust for number of somatic dis-
eases. This study used cross-sectional data and therefore
no causal inferences can be made. The study also has a
number of important strengths. Due to the large sample
size it was possible to adequately adjust for important
covariates. In addition to more traditional dimensional
anxiety indicators, we also examined the new DSM-5
anxious distress specifier. Furthermore, we not only
examined basal inflammatory markers, but also LPS-
stimulated inflammatory markers which give more insight
into the functioning and profile of the immune system
which is under strong genetic control. That the DSM-5
anxious distress specifier exhibited one of the strongest
associations with LPS-stimulated inflammation index
suggests that these five simple questions are enough to
select a group of MDD patients who are more homo-
geneous biologically than the MDD population as a whole.
With efforts to develop treatments for depression that
target immune dysregulation, it will be of interest to see
whether the DSM-5 specifier could serve as a means for
selecting patients suitable for such treatments.
Our study within a large MDD sample clearly indicates
that those MDD patients with anxious distress showed an
increased innate cytokine production capacity but no
higher basal inflammation. These results provide new
insight into the pathophysiology of MDD with concurrent
anxiety features, and contribute to the idea that the
anxious subtype of MDD is an individual subtype that
involves specific pathophysiology.
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